Deblina Raychaudhuri

CN-6, Sector 5, Salt Lake
Kolkata, WB 700091, India

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Spatiotemporal Regulation of Ligand Trafficking and TLR9 Activation by PIEZO1 in Human Plasmacytoid Dendritic Cells.

Spatiotemporal Regulation of Ligand Trafficking and TLR9 Activation by PIEZO1 in Human Plasmacytoid Dendritic Cells.

Journal: Research (Washington, D.C.)

Published: September 18, 2025

Loss of KDM6A-mediated genomic instability and metabolic reprogramming regulates response to therapeutic perturbations in bladder cancer.

Loss of KDM6A-mediated genomic instability and metabolic reprogramming regulates response to therapeutic perturbations in bladder cancer.

Journal: Nature communications

Published: June 18, 2025

Androgen receptor plays critical role in regulating cervical cancer cell migration.

Androgen receptor plays critical role in regulating cervical cancer cell migration.

Journal: Molecular and cellular endocrinology

Published: December 17, 2024

Histone Lactylation Drives CD8 T Cell Metabolism and Function.

Histone Lactylation Drives CD8 T Cell Metabolism and Function.

Journal: bioRxiv : the preprint server for biology

Published: June 10, 2024

Histone lactylation drives CD8+ T cell metabolism and function.

Histone lactylation drives CD8+ T cell metabolism and function.

Journal: Nature immunology

Published: November 15, 2023

Cutting Edge: ATP13A2 Is an Endolysosomal Regulator of TLR9/7 Activation in Human Plasmacytoid Dendritic Cells.

Cutting Edge: ATP13A2 Is an Endolysosomal Regulator of TLR9/7 Activation in Human Plasmacytoid Dendritic Cells.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: November 03, 2023

Myeloid-specific KDM6B inhibition sensitizes glioblastoma to PD1 blockade.

Myeloid-specific KDM6B inhibition sensitizes glioblastoma to PD1 blockade.

Journal: Nature cancer

Published: February 03, 2023

Immune checkpoint therapy-current perspectives and future directions.

Immune checkpoint therapy-current perspectives and future directions.

Journal: Cell

Published: January 27, 2023

Circulating Interleukin-8 Dynamics Parallels Disease Course and Is Linked to Clinical Outcomes in Severe COVID-19.

Circulating Interleukin-8 Dynamics Parallels Disease Course and Is Linked to Clinical Outcomes in Severe COVID-19.

Journal: Viruses

Published: November 01, 2022

Clinical Trial Subgroup Analyses to Investigate Clinical and Immunological Outcomes of Convalescent Plasma Therapy in Severe COVID-19.

Clinical Trial Subgroup Analyses to Investigate Clinical and Immunological Outcomes of Convalescent Plasma Therapy in Severe COVID-19.

Journal: Mayo Clinic proceedings. Innovations, quality & outcomes

Published: September 19, 2022

Myeloid cell-targeted therapies for solid tumours.

Myeloid cell-targeted therapies for solid tumours.

Journal: Nature reviews. Immunology

Published: May 12, 2022

Plasma Gradient of Soluble Urokinase-Type Plasminogen Activator Receptor Is Linked to Pathogenic Plasma Proteome and Immune Transcriptome and Stratifies Outcomes in Severe COVID-19.

Plasma Gradient of Soluble Urokinase-Type Plasminogen Activator Receptor Is Linked to Pathogenic Plasma Proteome and Immune Transcriptome and Stratifies Outcomes in Severe COVID-19.

Journal: Frontiers in immunology

Published: July 08, 2021

Showing 1-12 of 21

Last Updated: 09/26/2026